Processing

Please wait...

Settings

Settings

Goto Application

1. WO2020139116 - RECOMBINANT INHIBITOR OF HIV ENTRY

Publication Number WO/2020/139116
Publication Date 02.07.2020
International Application No. PCT/RU2018/000893
International Filing Date 28.12.2018
IPC
C07K 14/16 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus, human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. human immunodeficiency virus (HIV), visna-maedi virus, equine infectious anaemia virus
16HIV-1
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
A61K 38/16 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61P 31/18 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
CPC
A61K 38/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
A61P 31/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
18for HIV
C07K 14/16
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
15Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
155Lentiviridae, e.g. visna-maedi virus, equine infectious virus, FIV, SIV
16HIV-1 ; ; HIV-2
C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Applicants
  • ОБЩЕСТВО С ОГРАНИЧЕННОЙ ОТВЕТСТВЕННОСТЬЮ "БИОХАРТ" LIMITED LIABIBLITY COMPANY "BIOCHART" [RU]/[RU]
Inventors
  • ГАСАНОВ, Вагиф Али-Оглы GASANOV, Vagif Ali-Ogly
  • ШЕВАЛЬЕ, Александр Федорович SHEVALYE, Alexander Fedorovich
Priority Data
Publication Language Russian (RU)
Filing Language Russian (RU)
Designated States
Title
(EN) RECOMBINANT INHIBITOR OF HIV ENTRY
(FR) INHIBITEUR RECOMBINANT DE PÉNÉTRATION DU VIH
(RU) РЕКОМБИНАНТНЫЙ ИНГИБИТОР ПРОНИКНОВЕНИЯ ВИЧ
Abstract
(EN)
The invention relates to the field of biotechnology, in particular to the production of a recombinant peptide with prolonged action that inhibits the entry of HIV into a target cell. A recombinant peptide is expressed in E. coli cells, has a unique structure and contains three functional regions: a region that is homologous with the HIV CHR gp41, a region that promotes molecule dimerisation and a region that provides affinity with the cell membrane. The invention makes it possible to increase effectiveness in the treatment and prevention of AIDS.
(FR)
L'invention concerne le domaine de la biotechnologie et en particulier la production d'un peptide recombinant à durée d'action prolongée qui inhibe la pénétration du VIH dans une cellule cible. Le peptide recombinant est exprimé dans les cellules d'E. Coli, possède une structure unique et contient trois régions fonctionnelles : une région homologue à CHR gp41 du VIH, une région qui favorise la dimérisation de la molécule et une région qui assure l'affinité pour la membrane cellulaire. L'invention permet d'améliorer l'efficacité du traitement et de la prévention du SIDA.
(RU)
Изобретение относится к области биотехнологии, в частности к получению рекомбинантного пептида пролонгированного действия, ингибирующего проникновение ВИЧ в клетку-мишень. Рекомбинантный пептид экспрессирован в клетках E.coli, имеет уникальную структуру и содержит три функциональные области: область, гомологичную CHR gp41 ВИЧ, область, способствующую димеризации молекулы и область, обеспечивающую сродство с мембраной клетки. Изобретение позволяет повысит эффективность лечения и профилактики СПИДа.
Also published as
RU2019125952
Latest bibliographic data on file with the International Bureau